Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.
Also called NCT02577003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 143 participants
- Sponsor
- Registry
-
NCT02577003
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02577003. Randomized; double masking; primary purpose treatment. Start 2015-11-09 (registry gives no type); primary completion 2016-11-25 (actual). Results posted on 2018-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ipragliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02577003- Content hash
a014dec4acc96e402fff47f6590025cc3171ddac93a450dabbe172d744c3e31e